Fractionated dose of 225Ac-J591

Phase 1Radiopharmaceutical

WWeill Medical College of Cornell University

Fractionated dose of 225Ac-J591 is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 3

AAA817

Novartis

Phase 3

1 4

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 5

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 8

Duragesic

CCephalon

Preclinical

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 10

Osmitrol

BB. Braun Medical Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Prostate Cancer

NCT04506567

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·WWeill Medical College of Cornell University·Phase 1·NCT04506567·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fractionated dose of 225Ac-J591. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fractionated dose of 225Ac-J591 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fractionated dose of 225Ac-J591. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: WWeill Medical College of Cornell University

Fractionated dose of 225Ac-J591

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News